title: HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy.
authors.forename: O
authors.initials: O
authors.lastname: Ilhan
authors.forename: M
authors.initials: M
authors.lastname: Beksaç
authors.forename: H
authors.initials: H
authors.lastname: Koç
authors.forename: H
authors.initials: H
authors.lastname: Akan
authors.forename: A
authors.initials: A
authors.lastname: Keskin
authors.forename: O
authors.initials: O
authors.lastname: Arslan
authors.forename: G
authors.initials: G
authors.lastname: Gürman
authors.forename: M
authors.initials: M
authors.lastname: Ozcan
authors.forename: N
authors.initials: N
authors.lastname: Konuk
authors.forename: A
authors.initials: A
authors.lastname: Uysal
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D016001:Confidence Intervals; D005260:Female; D006684:HLA-DR Antigens / Q000097:blood* / Q000235:genetics; D015802:HLA-DR2 Antigen / Q000097:blood*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D014421:Turkey
chemical_list: D006684:HLA-DR Antigens; D015802:HLA-DR2 Antigen; D007166:Immunosuppressive Agents